List of Excipients in Branded Drug ESMOLOL HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	ACETIC ACID
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	HYDROCHLORIC ACID
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	SODIUM ACETATE
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	SODIUM CHLORIDE
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	SODIUM HYDROXIDE
West Ward Pharmaceutical Corporation	ESMOLOL HYDROCHLORIDE	esmolol hydrochloride	0641-2965	WATER

Generic Drugs Containing ESMOLOL HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Henry Schein Inc	esmolol hydrochloride	0404-9785	ACETIC ACID
Henry Schein Inc	esmolol hydrochloride	0404-9785	HYDROCHLORIC ACID
Henry Schein Inc	esmolol hydrochloride	0404-9785	SODIUM ACETATE ANHYDROUS
Henry Schein Inc	esmolol hydrochloride	0404-9785	SODIUM HYDROXIDE
Henry Schein Inc	esmolol hydrochloride	0404-9785	WATER
Henry Schein, Inc.	esmolol hydrochloride	0404-9858	ACETIC ACID

What are the Most Frequently-Used Excipients in ESMOLOL HYDROCHLORIDE?

# Of NDCs	Excipient
20	ACETIC ACID
20	HYDROCHLORIC ACID
16	SODIUM ACETATE
4	SODIUM ACETATE ANHYDROUS
5	SODIUM CHLORIDE
20	SODIUM HYDROXIDE

Excipient Strategy and Commercial Opportunities for Esmolol Hydrochloride

Last updated: February 25, 2026

What is the current excipient landscape for Esmolol Hydrochloride?

Esmolol Hydrochloride is an ultra-short-acting cardioselective beta-1 blocker primarily used for acute intravenous therapy in arrhythmias, tachycardia, and perioperative management. The formulation predominantly involves an injectable solution, requiring excipients that ensure stability, solubility, pH stability, and compatibility for IV administration.

Typical excipients used in Esmolol formulations

Excipients Category	Specific Components	Purpose	Regulatory Status	Notes
Buffering Agents	Sodium acetate, sodium citrate	Maintain pH (3.9–4.1)	Generally recognized as safe (GRAS)	pH stability critical for solubility
Solubilizers	Water for injection	Solvents for drug solubilization	U.S. FDA approved	Ensures drug dissolves uniformly
Preservatives	Occasional use of benzyl alcohol	Prevent microbial contamination	Caution in neonates	May influence excipient choices for safety
Co-solvents	None typically, but limited use of alcohols in some formulations	Enhance solubility	Regulatory restrictions	Strict due to potential toxicity

What are the strategic considerations for excipient selection?

1. Stability and Compatibility: Formulation must prevent degradation during storage; excipients should be inert with respect to Esmolol Hydrochloride. Buffering agents maintain pH, essential for stability.

2. Bioavailability and Solubility: Excipients should improve solubility for IV formulation without complicating manufacturing. Water for injection remains standard.

3. Safety Profile: Excipients must meet regulatory safety standards; preservatives and solvents are minimized or avoided in sensitive populations.

4. Regulatory Compliance: Use of excipients with established safety profiles (e.g., GRAS status) facilitates faster approval processes.

How can excipient innovation unlock commercial opportunities?

1. Developing Ready-to-Use (RTU) formulations

Reducing the need for pre-mixing or dilutions minimizes compounding errors. Incorporating stabilizers or buffer systems that extend shelf life enhances supply chain reliability. RTU formulations in pre-filled syringes could command premium pricing.

2. Formulating alternative delivery systems

• Liposomal or nanoparticulate systems: Encapsulation can reduce excipient-related side effects, prolong drug stability, and enable targeted delivery.
• Controlled-release formulations: Although less common for emergency drugs, controlled-release injectables could provide steady plasma levels for specific settings.

3. Utilizing novel excipients

• Synthetic or natural excipients with improved stability or compatibility profiles can reduce toxicological risks.
• Excipients that enable higher drug concentrations reduce volume requirements, beneficial for critical care settings.

4. Expanding indications with adjunct excipients

Inclusion of excipients that permit combination formulations, such as Esmolol with other fast-acting agents, can expand clinical applications and increase market share.

What are the patent and regulatory considerations?

• Patents may cover specific excipient combinations or formulations, providing exclusivity.
• Regulatory agencies (FDA, EMA) favor formulations with well-documented excipient safety profiles.
• New excipient systems or formulations may require extensive stability and safety testing, lengthening time to market.

Market and commercial outlook

• The global intravenous beta-blocker market is projected to grow annually by approximately 6% (Grand View Research, 2022), driven by increasing cardiovascular disease prevalence.
• Patent expiration of existing formulations opens opportunities for generic repeatability with optimized excipient systems.
• Investment in innovative formulations, such as pre-filled syringes with stabilized excipient systems, could command premium pricing and higher margins.
• Contract manufacturing organizations (CMOs) are exploring novel excipient combinations to serve niche markets seeking specialty formulations.

Key Opportunities Summary

• Optimize excipient systems to improve stability and shelf-life.
• Develop RTU formulations that reduce preparation errors and improve safety.
• Explore nanotechnology and controlled-release platforms.
• Incorporate novel excipients to invoke regulatory and manufacturing benefits.
• Leverage patent opportunities around specific excipient combinations.

Key Takeaways

• Excipient choice for Esmolol Hydrochloride centers on stability, solubility, safety, and regulatory compliance, mainly using buffers and water.
• Innovation in excipient systems and delivery formats can unlock new markets and premium pricing.
• Formulation improvements such as pre-filled syringes and nanoparticulate systems offer commercialization pathways.
• Regulatory approval remains a key hurdle but can be mitigated through leveraging established excipient safety data.
• Market growth in IV cardiovascular therapeutics supports investment in excipient and formulation innovation.

FAQs

1. What are the core excipients used in Esmolol Hydrochloride formulations?
Buffering agents like sodium acetate maintain pH; water for injection dissolves the drug; preservatives are used rarely due to safety concerns.

2. Can innovative excipients improve the stability of Esmolol solutions?
Yes. Novel stabilizers or buffers can extend shelf life, reduce degradation, and enable longer storage periods.

3. What delivery systems could benefit from excipient innovation?
Pre-filled syringes, liposomal formulations, and controlled-release injectables.

4. How does excipient selection influence regulatory approval?
Use of well-understood, safety-validated excipients accelerates approval and reduces potential hurdles.

5. Are there patent opportunities in excipient formulation for Esmolol?
Yes. Patents can cover specific excipient combinations, delivery formats, or stability systems, offering exclusivity advantages.

---

References

[1] Grand View Research. (2022). Intravenous cardiovascular therapeutics market analysis.
[2] U.S. Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Safety Evaluation of Excipient Systems.